Abstracts tagged "comparative effectiveness"

Abstract Number: 1432 • ACR Convergence 2022
Pharmacokinetic Evaluation of a Proposed Adalimumab Biosimilar MSB11022 versus the US-Licensed Reference Product: Results of a Randomized, Double-Blind, 3-Arm Parallel-Group, Single-Dose Trial in Healthy Subjects
Anna Dryja¹, Anna Lucia Buccarello², Isabelle Gaillard² and Joëlle Monnet², ¹MTZ Clinical Research Sp. z o.o.,, Warsaw, Poland, ²Fresenius Kabi Swiss BioSim, Eysins, Switzerland
Background/Purpose: Adalimumab, a recombinant fully human monoclonal immunoglobulin G1 antibody, is a biologic directed against tumor necrosis factor-alpha indicated for use in a range of…
Abstract Number: 1669 • ACR Convergence 2022
Comparing the Safety and Effectiveness of Methotrexate, TNF and IL6 Inhibitors for the Treatment of Checkpoint Inhibitor Arthritis
Anne Bass¹, Noha Abdel-Wahab², Pankti Reid³, Jeffrey Sparks⁴, Cassandra Calabrese⁵, Deanna Jannat-Khah, DrPH, MSPH⁶, Diviya Rajesh⁶, Nilasha Ghosh⁶, Komal Mushtaq⁷, Farah Al Haj⁸, Adewunmi Falohun⁹, Lydia Gedmintas¹⁰, Lindsey MacFarlane¹¹, Senada Arabelovic¹¹, Adi Diab², Ami Shah¹², Clifton O. Bingham III¹³, Karmela Kim Chan⁶ and Laura C. Cappelli¹⁴, ¹Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ²UT MD Anderson Cancer Center, Houston, TX, ³University of Chicago Medical Center, Chicago, IL, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Cleveland Clinic Foundation, Cleveland Heights, OH, ⁶Hospital for Special Surgery, New York, NY, ⁷Cleveland Clinic, Cleveland, OH, ⁸Sinai Grace Hospital/ Detroit Medical Center, Detroit, MI, ⁹MD Anderson Cancer Center, Houston, TX, ¹⁰Brigham and Women's Hospital, Boston, MA, ¹¹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ¹²Johns Hopkins Rheumatology, Baltimore, MD, ¹³Johns Hopkins University, Baltimore, MD, ¹⁴Johns Hopkins School of Medicine, Baltimore, MD
Background/Purpose: Immune checkpoint inhibitor associated arthritis (ICI-A) affects ∼4% of ICI-treated cancer patients and often persists. Given its long duration, it is important to identify…
Abstract Number: 1679 • ACR Convergence 2022
The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA (STOP-JIA) Study: Three-Year Outcomes
Yukiko Kimura¹, Sarah Ringold², George Tomlinson³, Laura Schanberg⁴, Anne Dennos⁵, MaryEllen Riordan⁶, Vincent Del Gaizo⁷, Katherine Murphy⁸, Pamela Weiss⁹, Brian Feldman¹⁰, Mei Sing Ong¹¹ and Marc Natter¹², ¹Hackensack Meridian Health, New York, NY, ²Janssen, Seattle, WA, ³University of Toronto, Toronto, ON, Canada, ⁴Duke University Medical Center, Durham, NC, ⁵Duke University, Durham, NC, ⁶Hackensack Meridian Health, Hackensack, NJ, ⁷CARRA, Inc, Washington, DC, ⁸CARRA, Inc, New Orleans, LA, ⁹Children's Hospital of Philadelphia, Glen Mills, PA, ¹⁰Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ¹¹Harvard Pilgrim Institute, Boston, MA, ¹²Boston Children's Hospital, Boston, MA
Background/Purpose: The CARRA STOP-JIA study compared the effectiveness of the CARRA Consensus Treatment Plans (CTPs) in achieving clinically inactive disease (CID) in untreated polyarticular JIA…
Abstract Number: 1841 • ACR Convergence 2022
To Combine or Not to Combine: Influence of Immunosuppressive Drug Combination in the Induction of Therapeutic Response in Non-infectious Uveitis
María Paula Álvarez Hernández¹, Alfredo Madrid-García², Alejandro Gómez Gómez³, Lara Borrego Sanz⁴, Rosalía Méndez Fernández⁴, Pedro Arriola Villalobos⁴, Esperanza Pato Cour⁵, David Díaz Valle⁴ and Luis Rodriguez-Rodriguez⁵, ¹Hospital Clínico San Carlos, Madrid, Spain, ²Instituto de Investigación Sanitaria San Carlos, Rheumatology, Madrid, Spain, Madrid, Spain, ³Hospital Infanta Sofia, Rheumatology, San Sebastián de los Reyes, Madrid, Spain, ⁴Instituto de Investigación Sanitaria San Carlos, Ophthalmology, Madrid, Spain, ⁵Instituto de Investigación Sanitaria San Carlos, Rheumatology, Madrid, Spain
Background/Purpose: Non-infectious uveitides (NIUs) include a heterogeneous group of sight-threatening and incapacitating conditions. Their correct management sometimes requires the use of immunosuppressive drugs (ISDs), prescribed…
Abstract Number: 0058 • ACR Convergence 2022
Health System Improvement in Inpatient ANA and Serologic Test Utilization
Saloni Goyal¹, Yasin kanakrieh¹, Marie O'Brien¹, Amy Slenker¹, Kathryn Zaffiri¹ and James Ross², ¹Lehigh Valley Health Network, Allentown, PA, ²lvhn, Macungie, PA
Background/Purpose: In 2005 Lehigh Valley Health Network (LVHN) instituted order sets for ANA serologic reflex testing with the objective to facilitate more efficient patient work-up…
Abstract Number: 0133 • ACR Convergence 2022
Retention Rate of Targeted Therapies in Erdheim-Chester Disease
Corrado Campochiaro¹, alessandro tomelleri¹, Francesco Pegoraro², Giovanni Galardi³, Nicola Farina⁴, Martina Mazzariol⁵, Francesco Catamerò⁶, Giacomo De Luca⁴, Giulio Cavalli⁴, Augusto Vaglio⁷ and Lorenzo Dagna⁸, ¹IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milano, Italy, ²Department of Health Sciences, University of Florence, Firenze, Italy, ³Department of Health Sciences, University of Florence, Florence, Italy, ⁴IRCCS San Raffaele Hospital - Vita-Salute San Raffaele University, Milano, Italy, ⁵University of Turin, Torino, Italy, ⁶Vita-Salute San Raffaele University, Milano, Italy, ⁷Azienda Ospedaliero Universitaria Meyer, Parna, Italy, ⁸IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milano, Italy
Background/Purpose: Erdheim-Chester disease (ECD) is a rare non-Langerhans histiocytosis with a broad clinical spectrum. The therapeutic landscape of ECD has remarkably changed over the last…
Abstract Number: 0576 • ACR Convergence 2022
Comparative Effectiveness of Osteoporosis (OP) Therapies Among a Population of Postmenopausal (PM) Women in the United States (U.S.)
Min Kim¹, Leah J McGrath², David Pritchard², Peter Samai², Jay Lin¹, Robert Kees Stad³, Leslie Spangler¹, Michele McDermott¹, Brian D Bradbury⁴ and M Alan Brookhart², ¹Amgen, Inc., Thousand Oaks, CA, ²NoviSci, Inc., Durham, NC, ³Amgen Inc., Zug, Switzerland, ⁴Amgen Inc., 1 Amgen Center Drive
Background/Purpose: Although clinical trials evaluating the efficacy of osteoporosis (OP) therapies have shown that denosumab (Dmab) significantly increases bone mineral density at pivotal sites compared…
Abstract Number: 0714 • ACR Convergence 2022
Real-World Treatment Effectiveness of Disease-Modifying Anti-Rheumatic Drugs by Serostatus Among Patients with Rheumatoid Arthritis
Yinzhu Jin, Jun Liu, Rishi Desai and Seoyoung Kim, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Serostatus may be associated with different responses to treatment with biologic disease-modifying anti-rheumatic drugs (DMARD) or Janus kinase inhibitors (JAKi) in patients with rheumatoid…
Abstract Number: 0934 • ACR Convergence 2022
Impact of Tapering Targeted Therapy on Disease Activity Is Different Based on Concomitant Methotrexate Use in Patients with Rheumatoid Arthritis: A Nationwide Cohort Study
Jun Won Park¹, Min Jung Kim², Hyoun-Ah Kim³, Jinhyun Kim⁴, Eun Bong Lee¹ and Kichul Shin⁵, ¹Seoul National University Hospital, Seoul, Republic of Korea, ²Seoul Metropolitan Government Boramae Medical center, Dongjak-gu, Seoul, Republic of Korea, ³Ajou University School of Medicine, Suwon, Republic of Korea, ⁴Chungnam National University Hospital, Jung-gu, Daejeon, South Korea, ⁵Seoul Metropolitan Government- Seoul National University Boramae Medical Center, Seoul, Republic of Korea
Background/Purpose: The American College of Rheumatology and the European League Against Rheumatism recommend using methotrexate (MTX) with targeted therapy. Previous studies have shown that tapering…
Abstract Number: L13 • ACR Convergence 2021
Efficacy and Safety of Subcutaneous Belimumab (BEL) and Rituximab (RTX) Sequential Therapy in Patients with Systemic Lupus Erythematosus: The Phase 3, Randomized, Placebo-Controlled BLISS-BELIEVE Study
Cynthia Aranow¹, Cornelia Allaart², Zahir Amoura³, Ian N Bruce⁴, Patricia Cagnoli⁵, Richard Furie¹, Paul Peter Tak⁶, Murray Urowitz⁷, Ronald van Vollenhoven⁸, Kenneth L Clark⁶, Mark Daniels⁹, Norma Lynn Fox¹⁰, Yun Irene Gregan¹⁰, James Groark¹¹, Robert B Henderson⁹, Mary Oldham⁹, Don Shanahan⁹, Andre van Maurik⁹, David A Roth¹⁰ and YK Onno Teng², ¹Feinstein Institutes for Medical Research, Northwell Health, Great Neck, NY, ²Leiden University Medical Center, Leiden, Netherlands, ³Centre National de reference pour le Lupus, Service de Medecine Interne 2, Institut E3M, Hopital Pitié-Salpétrière, Paris, France, ⁴NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Trust and Centre for Musculoskeletal Research, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁵University of Michigan Medical Center, Ann Arbor, MI, ⁶GlaxoSmithKline (At the time of the author's contribution to this study), Stevenage, United Kingdom, ⁷Toronto Western Hospital, University of Toronto, Lupus Clinic, Toronto, ON, Canada, ⁸Amsterdam University Medical Center, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁹GlaxoSmithKline, Stevenage, United Kingdom, ¹⁰GlaxoSmithKline, Collegeville, PA, ¹¹GlaxoSmithKline (At the time of the author's contribution to this study), Collegeville, PA
Background/Purpose: Disease control remains an unmet need in SLE. The rationale for sequential BEL and RTX therapy in SLE was previously published.1 This study evaluated…
Abstract Number: 0840 • ACR Convergence 2021
Modelling of Disease Activity in Patients with Inflammatory Arthropathies Treated with Etanercept Originator or Biosimilar as First-Line Biologic: A Real-World Observational Study Using the OPAL Dataset
Claire Deakin¹, Geoffrey Littlejohn², Hedley Griffiths³, Tegan Smith⁴, Catherine OSullivan⁵ and Paul Bird⁶, ¹OPAL Rheumatology Ltd, Sydney, Australia, ²Monash University, Melbourne, Australia, ³Barwon Rheumatology Service, Geelong, Australia, ⁴OPAL Rheumatology Ltd, Kogarah, Australia, ⁵OPAL Rheumatology Ltd, Queenscliff, Australia, ⁶University of New South Wales, Sydney, Australia
Background/Purpose: The availability of biosimilars as non-proprietary versions of established biologic disease-modifying anti-rheumatic drugs (bDMARDs) has increased around the world. Since April 2017 both the…
Abstract Number: 0938 • ACR Convergence 2021
Comparative Effectiveness and Treatment Survival of Different TNF Inhibitors for Axial Spondyloarthritis in Real-World Clinical Practice
Javier Marrugo¹, Maude Bonin¹, Gilles Boire¹, Louis Bessette² and Ariel Masetto¹, ¹Universite de Sherbrooke, Sherbrooke, QC, Canada, ²Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada
Background/Purpose: Tumor necrosis factor (TNF) inhibitors are the mainstay treatment for NSAID refractory axial spondyloarthritis (axSpA). However, few data exist on their use during routine…
Abstract Number: 0960 • ACR Convergence 2021
The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA (STOP-JIA) Study: 24-Month Outcomes
Yukiko Kimura¹, Sarah Ringold², George Tomlinson³, Laura Schanberg⁴, Anne Dennos⁵, Mary Ellen Riordan⁶, Vincent Del Gaizo⁷, Katherine Murphy⁸, Pamela Weiss⁹, Brian Feldman¹⁰, Marc Natter¹¹ and The STOP-JIA CARRA Registry Investigators¹², ¹Hackensack University Medical Center, New York, NY, ²Seattle Children's Hospital, Seattle, WA, ³University of Toronto, Toronto, ON, Canada, ⁴Duke University Medical Center, Durham, NC, ⁵Duke University, Durham, NC, ⁶Hackensack University Medical Center, Westwood, NJ, ⁷Childhood Arthritis & Rheumatology Research Alliance (CARRA), Whitehouse Station, NJ, ⁸Childhood Arthritis & Rheumatology Research Alliance (CARRA), New Orleans, LA, ⁹Children's Hospital of Philadelphia, Philadelphia, PA, ¹⁰The Hospital for Sick Children, Toronto, ON, Canada, ¹¹Boston Children's Hospital, Boston, MA, ¹²Childhood Arthritis & Rheumatology Research Alliance (CARRA), Milwaukee, WS
Background/Purpose: The CARRA STOP-JIA study compared the effectiveness of the CARRA Consensus Treatment Plans (CTPs) in achieving clinical inactive disease (CID) in untreated polyarticular JIA…
Abstract Number: 1072 • ACR Convergence 2021
The Multidisciplinary Approach with Patient Collaboration Improve the Clinical Effectiveness of the Intervention
Carlos González¹, Luis Menchén-Viso¹, Ofelia Baniandres-Rodriguez¹, Carmen Lobo-Rodríguez¹, Ana Herranz-Alonso¹, Ignacio Marín-Jiménez¹, Juan Carlos Nieto², Lucia Ibares-Frias¹, Indalecio Monteagudo¹, Esther Chamorro de Vega¹, Javier Torresano-Bruno¹, Amparo Lopez-Esteban¹, Arantza Ais-Larisgoitia¹, Paloma Morales de los Ríos Luna¹, ana Lopez-Calleja¹, Sonia Garcia de San Jose³ and Jose Maria Alvaro-Gracia³, ¹CEIMI, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Hospital General Universitario Gregorio Marañón, Madrid, Spain, ³Hospital General Universitario Gregorio Maranón, Madrid, Spain
Background/Purpose: We have developed a multidisciplinary unit for patients in treatment with biological therapies (BT) with the collaboration of Dermatology (Der), Gastroenterology (GE), Rheumatology (Rheu),…
Abstract Number: 1214 • ACR Convergence 2021
Examining the Relationship Between Shared Epitope, ACPA Seropositivity, and Real-World Drug Effectiveness in Patients with Rheumatoid Arthritis
Kristin Wipfler¹, Joshua Baker², Harlan Sayles³, Xue Han⁴, Sang Hee Park⁴, Keith Wittstock⁴, Ted Mikuls³ and Kaleb Michaud³, ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³University of Nebraska Medical Center, Omaha, NE, ⁴Bristol Myers Squibb, Princeton, NJ
Background/Purpose: The shared epitope (SE) is an amino acid sequence motif coded by several HLA-DRB1 alleles that are overrepresented among people with rheumatoid arthritis (RA).…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].